TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03418038

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow aspiration and biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Central Venous Cannula Insertion
Description: Undergo PICC placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Central Venous Cannula Insertion
Description: Undergo PICC placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Portacath Placement
Description: Undergo portacath placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Portacath Placement
Description: Undergo portacath placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study: NCT04690348

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Craniotomy
Description: Craniotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Craniotomy
Description: Craniotomy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cesium-131 brachytherapy
Description: Intracavitary Cesium-131 brachytherapy
Study: NCT03974178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexinidazole
Description: Tablets of 600 mg; Participants with a weight between 20 and 34 kg received 1200 mg (2 tablets) for 4 days, then 600 mg (1 tablet) for 6 days (with food); Participants with a weight of 35 kg and above received 1800 mg (3 tablets) for 4 days, then 1200 mg (2 tablets) for 6 days (with food)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexinidazole
Description: Tablets of 600 mg; Participants with a weight between 20 and 34 kg received 1200 mg (2 tablets) for 4 days, then 600 mg (1 tablet) for 6 days (with food); Participants with a weight of 35 kg and above received 1800 mg (3 tablets) for 4 days, then 1200 mg (2 tablets) for 6 days (with food)
Study: NCT05650788

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NMR spectrometry
Description: The MRI protocol will be carried out at 3 Tesla (3T) on a Siemens NMR imaging system (Magnetom Vida, Siemens Healthcare, Erlangen, Germany), the emission of radiofrequency waves and the reception of the signal will be done using a resonator in quadrature head (64-channel phase-array antenna). The MRI protocol will take place in two phases:~* Realization of a morphological sequence for the identification of the zone of interest.~* Acquisition of a 1D NMR spectrum in the ventral striatum (right and left).~* Acquisition of a 1D NMR spectrum in the anterior cingulate cortex (right and left).~* Acquisition of a 1D NMR spectrum in the prefrontal cortex (right and left).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NMR spectrometry
Description: The MRI protocol will be carried out at 3 Tesla (3T) on a Siemens NMR imaging system (Magnetom Vida, Siemens Healthcare, Erlangen, Germany), the emission of radiofrequency waves and the reception of the signal will be done using a resonator in quadrature head (64-channel phase-array antenna). The MRI protocol will take place in two phases:~* Realization of a morphological sequence for the identification of the zone of interest.~* Acquisition of a 1D NMR spectrum in the ventral striatum (right and left).~* Acquisition of a 1D NMR spectrum in the anterior cingulate cortex (right and left).~* Acquisition of a 1D NMR spectrum in the prefrontal cortex (right and left).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NMR spectrometry
Description: The MRI protocol will be carried out at 3 Tesla (3T) on a Siemens NMR imaging system (Magnetom Vida, Siemens Healthcare, Erlangen, Germany), the emission of radiofrequency waves and the reception of the signal will be done using a resonator in quadrature head (64-channel phase-array antenna). The MRI protocol will take place in two phases:~* Realization of a morphological sequence for the identification of the zone of interest.~* Acquisition of a 1D NMR spectrum in the ventral striatum (right and left).~* Acquisition of a 1D NMR spectrum in the anterior cingulate cortex (right and left).~* Acquisition of a 1D NMR spectrum in the prefrontal cortex (right and left).
Study: NCT00862433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha tocopherol
Description: intravenous deuterated vitamin E at doses of 2mg, 5mg, 7.5mg, 10mg and 30mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha tocopherol
Description: intravenous deuterated vitamin E at doses of 2mg, 5mg, 7.5mg, 10mg and 30mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha tocopherol
Description: intravenous deuterated vitamin E at doses of 2mg, 5mg, 7.5mg, 10mg and 30mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha tocopherol
Description: intravenous deuterated vitamin E at doses of 2mg, 5mg, 7.5mg, 10mg and 30mg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Deuterated vitamin E, oral and intravenous, at doses of 2mg, 5mg, 7.5mg, 10mg and 30mg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Deuterated vitamin E, oral and intravenous, at doses of 2mg, 5mg, 7.5mg, 10mg and 30mg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Deuterated vitamin E, oral and intravenous, at doses of 2mg, 5mg, 7.5mg, 10mg and 30mg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Deuterated vitamin E, oral and intravenous, at doses of 2mg, 5mg, 7.5mg, 10mg and 30mg.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Oral vitamin C, one gram daily.
Study: NCT03604692

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axatilimab
Description: axatilimab is a high affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). CSF-1R signaling has been demonstrated in nonclinical studies to be the key regulatory pathway involved in the expansion and infiltration of donor derived macrophages that mediate the disease processes involved in cGVHD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: axatilimab
Description: axatilimab is a high affinity antibody targeting the colony stimulating factor 1 receptor (CSF-1R). CSF-1R signaling has been demonstrated in nonclinical studies to be the key regulatory pathway involved in the expansion and infiltration of donor derived macrophages that mediate the disease processes involved in cGVHD.
Study: NCT01467427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonacog beta pegol
Description: A single dose of 40 U/kg will be administered intravenously, i.v. (into the vein) once weekly.
Study: NCT04144023

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Granulocyte-Macrophage Colony-Stimulating Factor
Description: Given intradermally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multi-epitope HER2 Peptide Vaccine H2NVAC
Description: Given intradermally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo standard of care surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study: NCT00882895

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell infusion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TLI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solumedrol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Study: NCT04535011

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PPKAY (brief intervention)
Description: PPKAY is a nurse-administered, one-on-one, 15-minute brief intervention (BI) for alcohol use using FRAMES motivational interviewing techniques. The BI is a four-step discussion: 1) Raise the Subject of Alcohol, 2) Provide Feedback, 3) Enhance Motivation 4) Negotiate and Advice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PPKAY (brief intervention)
Description: PPKAY is a nurse-administered, one-on-one, 15-minute brief intervention (BI) for alcohol use using FRAMES motivational interviewing techniques. The BI is a four-step discussion: 1) Raise the Subject of Alcohol, 2) Provide Feedback, 3) Enhance Motivation 4) Negotiate and Advice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PPKAY (brief intervention)
Description: PPKAY is a nurse-administered, one-on-one, 15-minute brief intervention (BI) for alcohol use using FRAMES motivational interviewing techniques. The BI is a four-step discussion: 1) Raise the Subject of Alcohol, 2) Provide Feedback, 3) Enhance Motivation 4) Negotiate and Advice.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Booster
Description: After discharge from the hospital, a standard motivational text message will be sent to their cell phone twice monthly for the duration of the study. In a rotating fashion, one of four standard motivational texts translated into Swahili will be sent to their cell phones.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Booster
Description: After discharge from the hospital, a personalized motivational text message will be sent to participant cell phones twice monthly for the duration of the study. In a rotating fashion, one of four personalized motivational texts will be sent to their cell phones. Personalized texts will be created with the content obtained from the motivational interview sessions. At each session, the research nurse conducting the intervention will record four messages based on the content of the session to be sent as the Personalized Booster.
Study: NCT02240862

Intervention type: DEVICE
Intervention: Carotid Artery Stent
Description: Placement of a stent within the carotid artery
Study: NCT03881696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab will be supplied in pre-filled syringes (PFS). PFS of omalizumab will be provided to the clinical research units as 75 mg and 150 mg dosage forms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab will be supplied in pre-filled syringes (PFS). PFS of omalizumab will be provided to the clinical research units as 75 mg and 150 mg dosage forms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab will be supplied in pre-filled syringes (PFS). PFS of omalizumab will be provided to the clinical research units as 75 mg and 150 mg dosage forms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab will be supplied in pre-filled syringes (PFS). PFS of omalizumab will be provided to the clinical research units as 75 mg and 150 mg dosage forms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab will be supplied in pre-filled syringes (PFS). PFS of omalizumab will be provided to the clinical research units as 75 mg and 150 mg dosage forms.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Omalizumab
Description: Placebo contains the same ingredients as the omalizumab formulation, excluding omalizumab. Placebo will be supplied in pre-filled syringes (PFS). PFS of placebo will be provided to the clinical research units as 75 mg and 150 mg dosage forms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multi-Allergen Oral Immunotherapy
Description: Multi-allergen OIT will be any of the following drug products: peanut, milk, egg, wheat, cashew, hazelnut, and walnut (all food protein flours).~A prescription for each participant for the appropriate dose of each of the allergens will be prepared. The pharmacist will compound the appropriate allergens and dispense the Multi-allergen OIT dose in a blinded (masked) fashion. The Clinical Research Unit (CRU) staff will administer food flour to the participant orally in an age-appropriate food vehicle (e.g., applesauce, pudding, etc.). Dosage will be administered according to the study protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Multi-Allergen Oral Immunotherapy
Description: Oat flour will be used for placebo for Multi-allergen OIT. Route: by mouth/oral. Dosage will be administered according to the study protocol.

Intervention type: OTHER
Group type: OTHER
Intervention: Double-Blind Placebo-Controlled Food Challenge Based Treatment
Description: Each participant will receive a separate treatment plan for peanut and each of the two other participant-specific foods. A treatment plan will include instructions for one of the following:~* Long-term follow-up with dietary consumption of a food; or~* Long-term follow-up with avoidance of a food; or~* Rescue OIT for a food. The treatment plan for each food may change depending on a participant's response to prescribed treatment over time.
Study: NCT01372943

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: synthetic stool or pure cultures of probiotic intestinal bacteria
Description: synthetic stool or pure cultures of probiotic intestinal bacteria from healthy donor stool that can be used as an enema to replace the use of stool transplant, for treatment of recurrent and refractory CDI
Study: NCT00788099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plitidepsin and Sorafenib
Description: Patients will receive i.v. plitidepsin over 1h on days 1, 8 and 15 every 4 weeks (d1, 8, 15 q4wk) and continuous oral sorafenib twice daily (bid) (a cycle is defined as an interval of 4 weeks).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Plitidepsin
Description: Patients will receive i.v. gemcitabine over 30 minutes followed 1 hour later by plitidepsin over 1 hour on d1, 8, 15 q4wk (a cycle is defined as an interval of 4 weeks).
Study: NCT03621371

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive therapy
Description: Metacognitive therapy is a form av cognitive-behavioral therapy which aims to change cognitions about worry in patients with generalized anxiety disorder.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intolerance of uncertainty therapy
Description: Intolerance of uncertainty therapy is a form av cognitive-behavioral therapy which aims to reduce cognitive and behavioral avoidance of uncertain situations or cognitions which lead to worry in patients with generalized anxiety disorder.
Study: NCT02606422

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active HD-tDCS plus Speech-Language Therapy
Description: Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2mA (estimated current density 0.04 mA/cm2; estimated total charge 0.048C/cm2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be oral and written naming.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham plus Speech-Language Therapy
Description: Speech-language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will be oral and written naming.
Study: NCT02108054

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7T MRI
Description: Modifying, refining, and verifying the feasibility and applicability of tasks for functional magnetic resonance imaging (fMRI) to measure intended concomitant brain activation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7T MRI
Description: Modifying, refining, and verifying the feasibility and applicability of tasks for functional magnetic resonance imaging (fMRI) to measure intended concomitant brain activation
Study: NCT03819933

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational intervention
Description: Investigators will first determine preferred language and approaches by families, then redefine current training for prenatal counseling at extreme prematurity by developing and implementing two novel, interdisciplinary simulation-based educational programs for MFM and Neonatology (a workshop and an online module), focusing on eliciting values and building partnerships through advanced communication and relational skills, to improve counseling practices and outcomes
Study: NCT02373215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine HCL ER
Description: Nalbuphine HCL extended release tablet
Study: NCT02135302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eravacycline
Description: Eravacycline (TP-434) is a parenteral and oral antibiotic of the tetracycline class that is highly active in vitro and in established animal infection models against both nosocomial and community-acquired methicillin-susceptible or -resistant Staphylococcus aureus strains, vancomycin-susceptible or -resistant Enterococcus faecium and Enterococcus faecalis, and penicillin-susceptible or -resistant strains of Streptococcus pneumoniae. In addition, eravacycline is highly active against clinically important species of Enterobacteriaceae (including those isolates that produce extended-spectrum β-lactamases and/or are carbapenem-resistant), Acinetobacter baumannii, and anaerobes.
Study: NCT01897480

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2875358
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Administered Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Administered Orally
Study: NCT03576001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Undecanoate
Description: administered through injections by study staff

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hybrid exercise
Description: hybrid exercise: functional electrical stimulation of lower extremity with leg cycling (FES-LC) and arm ergometry, supervised for two weeks and then home-based

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: hybrid exercise
Description: hybrid exercise: functional electrical stimulation of lower extremity with leg cycling (FES-LC) and arm ergometry, supervised for two weeks and then home-based
Study: NCT04774848

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Frequency Oscillatory Ventilator
Description: HFOV uses a piston diaphragm to generate alternating positive and negative pressure changes to give breaths of 300 to 900/min (5-15 Hz) given over a set mean airway pressure. Both inhalation and exhalation are active.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High Frequency Oscillatory Ventilator
Description: HFOV uses a piston diaphragm to generate alternating positive and negative pressure changes to give breaths of 300 to 900/min (5-15 Hz) given over a set mean airway pressure. Both inhalation and exhalation are active.
Study: NCT01628640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta
Description: Given intratumorally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta
Description: Given intratumorally
Study: NCT02307396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimozide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perazine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perazine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluphenazine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluphenazine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flupentixole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flupentixole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertindole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertindole
Study: NCT03288181

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muscle Stretch
Description: The splint will be applied to the affected leg as per the protocol for 30 minutes per day, 5 days per week for 4 weeks.
Study: NCT03552068

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Treatment (placebo) will be taken during 8 weeks with one visit at 2, 4 and 8 weeks.~Medication: placebo twice a day (in the morning and evening).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: Treatment will be taken during 8 weeks with one visit at 2, 4 and 8 weeks. Medication: 75 μg of clonidine twice a day (in the morning and evening).
Study: NCT01112241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol plus tiotropium
Description: Four separate doses of 100 μg of albuterol and 18 μg of tiotropium bromide. Albuterol will be given by a metered-dose inhaler connected to a valved-holding chamber and tiotropium by a dry-powder device.